Health By Bob Tedeschi For cancer patients, newest treatments force the ultimate decision, with no room for error
Biotech By Sharon Begley Beware the hype: Top scientists cautious about fighting cancer with immunotherapy
First Opinion By Raymond J. Tesi Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay
Politics By Casey Ross Medicare proposes a boost in payments for CAR-T and other breakthrough drugs and devices
First Opinion By Neil Canavan Cartoons offer a peek into cancer immunotherapy — and scientists’ minds
First Opinion By Doreen Carvajal Male doctors said my ‘female’ cancer was incurable. Then a woman took command and gave me hope
Adam's Take By Adam Feuerstein A biotech seeking IPO riches limited disclosure of patient deaths tied to immunotherapy
Lab Chat By Megan Thielking Insight into exhausted immune cells could open new doors for cancer therapy
Biotech By Damian Garde Novel cancer treatment from Kite Pharma notches positive results, but big questions remain
In the Lab By Sharon Begley In cancer, it’s back to the future as old treatments make cutting-edge ones more effective
Health By Rebecca Robbins For cancer patients on experimental immunotherapy drugs, it’s been an emotional week
Biotech By Damian Garde and Meghana Keshavan Juno halts its immunotherapy trial for cancer after three patient deaths
Politics By Dylan Scott As Johns Hopkins launches new cancer center, Biden sees a model for his ‘moonshot’
Quick Take By Megan Thielking These antibodies could protect against Ebola’s harms, but results come with a caveat
In the Lab By Rebecca Robbins and Sharon Begley Rival drug firms team up to test new approach to cancer treatment